Full Text View
Tabular View
Study Results
Related Studies
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
This study has been completed.
Study NCT00367835   Information provided by Shire Development LLC

First Received on August 22, 2006.   Last Updated on October 7, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
ADHD
Additional conditions recognized in this trial
Attention Deficit Disorder with Hyperactivity
More general conditions related to this trial
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders
Mental Disorders Diagnosed in Childhood
Interventions listed in this trial
SPD503 (Guanfacine hydrochloride)
Placebo
Additional drug interventions recognized in this trial
Guanfacine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Shire Development LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services